Formulated for female reproductive health.
FertilOva Plus is an advanced food supplement formulated for female reproductive health.
About FertilOva Plus
FertilOva Plus supports women who may be having difficulty conceiving, as it can help promote regular ovarian function, support regular menstrual cycles and may help increase egg quality.
Who should use FertilOva Plus?
FertilOva Plus has been developed for women suffering with Polycystic Ovary Syndrome (PCOS). (see study references 8,9,10,11). Research has shown that Inositol improves the way the body uses insulin and promotes normal hormone levels, which in turn promotes regular menstrual cycles and normal ovulatory function. Recent studies have shown that taking a combination of Myo and D-Chiro-Inositol, in the body’s naturally occurring ratio of 40:1, is more beneficial than taking Myo or D-Chiro alone (5,6).
Folic acid, another ingredient in FertilOva Plus, is a water-soluble vitamin belonging to the B-group vitamins Folic acid plays a key role in the metabolism of amino acids in the protein and fusion and recovery of chromosomes and therefore is a key factor for normal cell division and tissue growth. Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. It is characterized by chronic anovulation, hyperandrogenism, and insulin resistance. It is the main cause of infertility due to the menstrual dysfunction and metabolic disorders.
Women with PCOS also have an increased cardiovascular risk because of dyslipidemia and insulin resistance. So far, Myo-inositol (MI) and D-chiro-inositol, two inositol stereoisomers, have been proven to be effective in PCOS treatment. However, only MI has been shown to have beneficial effects on reproductive function, whereas the administration of MI/D-chiro-inositol, in the physiological plasma ratio (i.e., 40:1) ensures better clinical results, such as the reduction of insulin resistance, androgens’ blood levels, cardiovascular risk and regularization of menstrual cycle with spontaneous ovulation (1,7,8). Between 65- 80% of patients with PCOS have insulin resistance, where the response to insulin is sub-optimal. This condition is thought to contribute to a number of other issues related to PCOS, such as metabolic syndrome, hormonal imbalance, androgenic symptoms and diabetes in pregnancy. PCOS patients have a higher risk than normal of developing the metabolic syndrome; a mix of conditions including weight gain, type 2 diabetes and dyslipidaemia. Approximately one third to one half of all women and adolescent girls with PCOS have the metabolic syndrome.
A recent RCOG ‘green top’ guideline advises doctors to inform patients with PCOS of such long-term health consequences. Such patients have considerable long-term health risks and the evidence for using FertilOva Plus in these patients is compelling.